Allergy Testing For Allergic Rhinitis Allergic Articles & Analysis: Older
24 news found
As we move towards the New Year, we’ll be anxiously awaiting the warming days of springtime. Well, most of us will anyway. Fortunately for many of us, and unfortunately for many others, it means flowers will be in bloom after spring rains and some of us will be suffering with seasonal allergic rhinitis, more commonly referred to as hay fever. It’s all about the coughing, the red ...
Nasal obstruction remains a challenge to the modem day rhinologist. In the evolving climate of "cost containment" and "risk-outcome analyses", office-based inferior turbinate reduction has regained popularity. This article describes a new method to reduce nasal obstruction in patients with chronic rhinitis when conventional medical therapy has failed. Rhinitis is chronic (CR) when symptoms of ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. Judith Ng Cashin, M.D., has joined the company as Chief Medical Officer effective as of October 1, 2018. "Dr. Ng Cashin has ...
Wines, for instance, if they are not ecologically sourced, might contain sulfites, a preservative that grape growers dust over grapes in the weeks leading up to harvest. Sulfites can trigger allergy-like reactions to sensitized people, such as wheezing in those suffering from asthma, allergic rhinitis, and urticaria[3]. ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has expanded the marketing authorization for Dupixent (dupilumab) in the European Union. Dupixent is now also approved in children aged 6 to 11 years as an add-on maintenance treatment for severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised ...
Hay fever, also known as allergic rhinitis, occurs when allergens like pollen enter the body and the immune system mistakenly identifies them as a threat. For those with allergic rhinitis, the body then responds to the allergen by releasing chemicals that can cause symptoms. ...
HAMILTON, BERMUDA / ACCESSWIRE / February 9, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the geographic scope of its existing marketing and distribution agreement (the "Agreement") for Bentrio™ with Wellesta Holding Pte Ltd ("Wellesta") has been expanded. In addition to ...
HAMILTON, BERMUDA / ACCESSWIRE / February 7, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced today that it has entered into an agreement for the marketing and distribution of Bentrio™ (the "Agreement"), its nasal spray for protection against airborne viruses and allergens, with Avernus ...
The American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), in partnership with Intersect ENT, Inc., launched a public education campaign that provides clinically-developed information by experts in the field aimed at helping people better understand their nasal and sinus symptoms. World Sinus Health Awareness Day, with its inaugural celebration on September 29, has an ...
AOBiome’s 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Mass., June 30, 20120/PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis based on positive clinical trial results related to the ...
AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation, announced initiation of a Phase 2b clinical trial in pruritus (itch) associated with atopic dermatitis based on positive clinical trial results related to the investigation of its lead product candidate, B244, in patients with atopic dermatitis (eczema) in a Phase 2a clinical trial in ...
Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of ...
Evolve BioSystems, Inc., a global leader dedicated to improving human health through the gut microbiome, today announced a collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to conduct a clinical study in children at risk for developing atopic dermatitis. The study will assess the effects of introducing a specific gut ...
Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the appointment of Robert "Bob" Pomrenke to the position of Chief Executive Officer, effective April 1, 2019. Mr. Pomrenke brings over 25 years of sales, marketing and business development experience in the allergy immunotherapy market. ...
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic diseases, today announced the administering of its lead product candidate, B244, to the first patient in the Company’s Phase 1b clinical trial to treat pediatric ...
AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s Ammonia ...
Neurent Medical's rhinitis device delivers radio frequency energy in a focused and controllable zone of effect, causing minimal collateral damage to surrounding tissues LONDON, Nov. 13, 2018 /CNW/ -- Based on its recent analysis of the European rhinitis therapy market, Frost & Sullivan recognises Neurent Medical with the 2018 European New Product Innovation Award for developing a ...
HAL Allergy B.V. today announced the registration of SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml in Germany. These are the first marketing authorisations granted by the Paul Ehrlich Institute following the German Therapieallergene-Verordnung (TAV). The TAV was initiated by the German Federal Ministry of Health on 14 November, 2008, and regulates the marketing ...
AOBiome Therapeutics, Inc. ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the expansion of its Board of Directors with the appointments of (i) Professor Klaus Dugi, Executive Vice President and Chief Medical Officer of ...
AOBiome Therapeutics ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the election of Jun Wang, Ph.D., founder and CEO of iCarbonX, as Chairman of AOBiome's Board of Directors, effective May 31, 2018. Dr. Wang has served on ...